Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 45Carcinoma, Renal Cell 19Neoplasm Metastasis 16Leukemia, Myeloid, Acute 15Kidney Neoplasms 14Skin Neoplasms 11Neoplasms 10Leukemia 7Breast Neoplasms 7Lymphoma, Non-Hodgkin 6Myelodysplastic Syndromes 5Ovarian Neoplasms 4Neuroblastoma 4Congenital Abnormalities 4Colorectal Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hodgkin Disease 3Uveal Melanoma 2Prostatic Neoplasms 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Myeloid 1Sarcoma, Ewing 1Sarcoma 1

Interventions

Cisplatin 24Paclitaxel 18Carboplatin 18pembrolizumab 12Gemcitabine 12Radiotherapy 9Fluorouracil 9Specimen Handling 8Magnetic Resonance Spectroscopy 7cemiplimab 6Platinum 6Nivolumab 6Docetaxel 6Cetuximab 61,2-diaminocyclohexaneplatinum II citrate 6epothilone B 5anlotinib 5Sunitinib 5Pemetrexed 5Oxaliplatin 5Everolimus 5Drug Therapy 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5durvalumab 4Radiotherapy, Intensity-Modulated 4Radiation 4Erlotinib Hydrochloride 4Celecoxib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma × Interleukin-2 × Clear all
NCT05115500 2021-11-10

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
55 enrolled
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡